Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 2: 152 - 161

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.02.003

Basic research

Expression and clinical significance of PLA2G2A in kidney renal papillary cell carcinoma

  • Fang LI ,
  • Kaiyang LI ,
  • Jue WANG ,
  • Ruiyang YAN ,
  • Hui SHEN ,
  • Min LIU
Expand
  • 1.School of Basic Medicine, Medical School of Yan'an University, Yan'an 716000, China
    2.Department of Oncology, Yan'an University Affiliated Hospital, Yan'an 716000, China
LIU Min, E-mail: ydfylm@163.com.

Received date: 2022-08-26

  Accepted date: 2023-01-12

  Online published: 2023-02-28

Supported by

Natural Science Basic Program of Shaanxi Province(2022JQ-907);Shaanxi University Science and Technology Association Youth Talent Promotion Project(20210309);2022 Provincial College Students Innovation and Entrepreneurship Training Program Project(S202210719089)

Fold

Abstract

Objective ·To investigate the expression and clinical significance of phospholipase A2 Group ⅡA (PLA2G2A) in kidney renal papillary cell carcinoma (KIRP), and provide new ideas for seeking KIRP targets. Methods ·The expression level of PLA2G2A in pan-cancer and its relationship with prognosis and immune infiltration were analyzed by online software SangerBox. On this basis, the expression level of PLA2G2A in KIRP was analyzed with the help of the UCSC xena database; the correlation between PLA2G2A expression and prognosis and immune infiltration of KIRP were analyzed by using the UALCAN database and the TIMER database, respectively. In addition, the LinkedOmics database was used to analyze the related genes, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment of PLA2G2A in KIRP. Results ·PLA2G2A was significantly low expressed in 15 tumor samples from The Cancer Genome Atlas (TCGA) including KIRP. It was further validated that PLA2G2A was significantly lower expressed in KIRP with the help of Genotype-Tissue Expression (GTEx) database. The expression level of PLA2G2A was closely related to the prognosis and immune infiltration of various tumors. The higher the expression level of PLA2G2A in KIRP was, the worse the prognosis and the higher the abundance of immune infiltration were. GO analysis showed that PLA2G2A was mainly enriched in biological regulation and metabolic process in biological process (BP), cell membrane and nucleus in cell component (CC), and protein binding and ion binding in molecular function (MF). KEGG pathway enrichment analysis suggested that the pathways positively correlated with PLA2G2A were enriched in ribosome, cell cycle, proteasome, systemic lupus erythematosus and antigen processing and presentation, while the pathways negatively correlated with PLA2G2A were enriched in citrate cycle, pyruvate metabolism, and carbon metabolism. Conclusion ·PLA2G2A is significantly lower expressed in KIRP. Unexpectedly, the higher the expression level of PLA2G2A in KIRP is, the worse the prognosis and the higher the abundance of immune infiltration are. In KIRP, the PLA2G2A positively correlated pathways are mainly enriched in cell cycle and immune-related pathways (such as systemic lupus erythematosus, antigen processing and presentation), while the negatively correlated pathways are mainly concentrated in citric acid cycle and pyruvate metabolism signaling pathways. Thus, it is needed to be further explored whether PLA2G2A plays a role in the development of KIRP as a tumor suppressor or an oncogene.

Key words： phospholipase A2 group ⅡA (PLA2G2A); kidney renal papillary cell carcinoma (KIRP); pan-cancer; prognosis; immune infiltration

Cite this article

Fang LI , Kaiyang LI , Jue WANG , Ruiyang YAN , Hui SHEN , Min LIU . Expression and clinical significance of PLA2G2A in kidney renal papillary cell carcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(2) : 152 -161 . DOI: 10.3969/j.issn.1674-8115.2023.02.003

References

1 RHOADES SMITH K E, BILEN M A. A review of papillary renal cell carcinoma and MET inhibitors[J]. Kidney Cancer, 2019, 3(3): 151-161.
2 AKINKUOLIE A O, LAWLER P R, CHU A Y, et al. Group ⅡA secretory phospholipase A2, vascular inflammation, and incident cardiovascular disease[J]. Arterioscler Thromb Vasc Biol, 2019, 39(6): 1182-1190.
3 SHIN D, CHANG S Y, BOGERE P, et al. Beneficial roles of probiotics on the modulation of gut microbiota and immune response in pigs[J]. PLoS One, 2019, 14(8): e0220843.
4 孙梅, 姜潇, 王朝晖. PLA2G2A基因在胃癌前病变组织中的表达及意义[J]. 中国医药指南, 2012, 10(34): 175-176.
4 SUN M, JIANG X, WANG C H. Expression and significance of PLA2G2A in precancerous tissues of gastric cancer[J]. Guide of China Medicine, 2012, 10(34): 175-176.
5 翟艳春, 魏文强, 何燕, 等. 磷脂酶A2-ⅡA亚型基因rs11677 C/T多态位点基因突变及蛋白表达与食管鳞状细胞癌临床病理特征的关联性研究[J]. 中国全科医学, 2015, 18(12): 1396-1400.
5 ZHAI Y C, WEI W Q, HE Y, et al. Association of gene mutation and protein expression of rs11677 C/T polymorphism in phospholipase A2-ⅡA subtype gene with clinicopathological features of esophageal squamous cell carcinoma[J]. Chinese General Practice, 2015, 18(12): 1396-1400.
6 FIJNEMAN R J A, CORMIER R T. The roles of sPLA2-ⅡA (Pla2g2a) in cancer of the small and large intestine[J]. Front Biosci, 2008, 13: 4144-4174.
7 PRAML C, AMLER L C, DIHLMANN S, et al. Secretory type Ⅱ phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa[J]. Oncogene, 1998, 17(15): 2009-2012.
8 MACPHEE M, CHEPENIK K P, LIDDELL R A, et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia[J]. Cell, 1995, 81(6): 957-966.
9 洪双双. PLAG1和PLA2G2A在肝癌中的异常表达[D]. 郑州: 郑州大学, 2011.
9 HONG S S. Abnormal expression of PLAG1 and PLA2G2A in liver cancer[D]. Zhengzhou: Zhengzhou University, 2011.
10 GRAFF J R, KONICEK B W, DEDDENS J A, et al. Expression of group Ⅱa secretory phospholipase A2 increases with prostate tumor grade[J]. Clin Cancer Res, 2001, 7(12): 3857-3861.
11 赵久达, 贺菊香, 耿排力. PLA2GⅡA基因在胃癌组织的表达及意义[J]. 山东医药, 2006, 46(10): 24-25.
11 ZHAO J D, HE J X, GENG P L. Expression and significance of PLA2GⅡA gene in gastric cancer[J]. Shandong Medical Journal, 2006, 46(10): 24-25.
12 GANESAN K, IVANOVA T, WU Y H, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel β-catenin/TCF target gene[J]. Cancer Res, 2008, 68(11): 4277-4286.
13 韩松辰, 殷华奇, 徐涛. 基于肾癌肿瘤微环境的免疫治疗研究进展[J]. 中国医学科学院学报, 2022, 44(2): 305-312.
13 HAN S C, YIN H Q, XU T. Research progress of immunotherapy based on tumor microenvironment in renal cell carcinoma[J]. Acta Academiae Medicinae Sinicae, 2022, 44(2): 305-312.
14 ZHANG S C, ZHANG E D, LONG J H, et al. Immune infiltration in renal cell carcinoma[J]. Cancer Sci, 2019, 110(5): 1564-1572.
15 殷月玲, 于晓东. 甲状腺癌细针穿刺组织中S100A13、FOXA1表达量与细胞周期、细胞侵袭的相关性[J]. 海南医学院学报, 2018, 24(1): 71-74.
15 YIN Y L, YU X D. Correlation of S100A13 and FOXA1 expression with cell cycle and cell invasion in fine needle aspiration tissue of thyroid carcinoma[J]. Journal of Hainan Medical University, 2018, 24(1): 71-74.
16 LEVIN G, KOGA B A A, BELCHIOR G G, et al. Production, purification and characterization of recombinant human R-spondin1 (RSPO1) protein stably expressed in human HEK293 cells[J]. BMC Biotechnol, 2020, 20(1): 5.
17 刘鹏, 赵海玲, 马亮, 等. PPARGC1A基因多态性与中国汉族人群2型糖尿病患者肾脏疾病风险的研究[J]. 中国中西医结合肾病杂志, 2020, 21(10): 866-870.
17 LIU P, ZHAO H L, MA L, et al. Association of PPARGC1A gene polymorphism with renal disease risk in Chinese Han population with type 2 diabetes mellitus[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2020, 21(10): 866-870.
18 HERZIG S, SHAW R J. AMPK: guardian of metabolism and mitochondrial homeostasis[J]. Nat Rev Mol Cell Biol, 2018, 19(2): 121-135.
19 KUEFNER M S, PHAM K, REDD J R, et al. Secretory phospholipase A2 group ⅡA modulates insulin sensitivity and metabolism[J]. J Lipid Res, 2017, 58(9): 1822-1833.
Options
Outlines

/

〈 〉